Cargando…
Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review
Cancer diagnosis and therapeutics have been traditionally based on pathologic classification at the organ of origin. The availability of an unprecedented amount of clinical and biologic data provides a unique window of opportunity for the development of new drugs. What was once treated as a homogene...
Autores principales: | Mansinho, André, Fernandes, Ricardo Miguel, Carneiro, António Vaz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070286/ https://www.ncbi.nlm.nih.gov/pubmed/36418841 http://dx.doi.org/10.1007/s12325-022-02362-4 |
Ejemplares similares
-
Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine
por: Seligson, Nathan D., et al.
Publicado: (2020) -
The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022) -
Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021) -
Utilization of model-agnostic explainable artificial intelligence frameworks in oncology: a narrative review
por: Ladbury, Colton, et al.
Publicado: (2022) -
Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)